Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:OTLK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOTLKOutlook Therapeutics$1.40-6.4%$1.72$0.87▼$12.85$44.82M0.54748,986 shs486,421 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOTLKOutlook Therapeutics-0.99%-2.92%-4.17%+1.70%-82.68%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationOTLKOutlook Therapeutics1.711 of 5 stars3.43.00.00.01.20.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOTLKOutlook Therapeutics 2.80Moderate Buy$10.20628.57% UpsideCurrent Analyst Ratings BreakdownLatest OTLK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/24/2025OTLKOutlook TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$33.00 ➝ $24.002/18/2025OTLKOutlook TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.00 ➝ $3.002/18/2025OTLKOutlook TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $3.001/17/2025OTLKOutlook TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.001/17/2025OTLKOutlook TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00(Data available from 3/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOTLKOutlook TherapeuticsN/AN/AN/AN/A($1.57) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOTLKOutlook Therapeutics-$75.37M-$7.42N/AN/AN/AN/AN/A-225.12%5/21/2025 (Estimated)Latest OTLK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/14/2025Q1 2025OTLKOutlook Therapeutics-$0.85-$0.89-$0.04$0.72N/AN/A12/27/2024Q4 2024OTLKOutlook Therapeutics-$0.83-$0.77+$0.06$0.76N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthOTLKOutlook TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOTLKOutlook TherapeuticsN/A0.320.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOTLKOutlook Therapeutics11.20%Insider OwnershipCompanyInsider OwnershipOTLKOutlook Therapeutics4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableOTLKOutlook Therapeutics2032.02 million30.48 millionOptionableOTLK HeadlinesRecent News About These CompaniesOutlook Therapeutics management to meet virtually with BTIGMarch 21, 2025 | markets.businessinsider.comOutlook Therapeutics files to sell 21.72M shares of common stock for holdersMarch 21, 2025 | markets.businessinsider.comFBI warns about ransomware for Gmail, Outlook usersMarch 19, 2025 | abccolumbia.comOutlook Therapeutics expands share authorizationMarch 16, 2025 | investing.comOutlook Therapeutics Issues Convertible Note to AvondaleMarch 14, 2025 | tipranks.comOutlook Therapeutics resubmits BLA for ONS-5010 for treatment of wet AMDMarch 1, 2025 | ophthalmologytimes.comOutlook Therapeutics files to sell 7.07M shares of common stock for holdersMarch 1, 2025 | markets.businessinsider.comOutlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug AdministrationFebruary 28, 2025 | globenewswire.comOutlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand ConferenceFebruary 19, 2025 | globenewswire.comOutlook Therapeutics price target lowered to $10 from $12 at GuggenheimFebruary 19, 2025 | markets.businessinsider.comOutlook Therapeutics price target lowered to $3 from $30 at H.C. WainwrightFebruary 18, 2025 | markets.businessinsider.comOutlook Therapeutics reports Q1 adjusted EPS (89c) vs. (78c) last yearFebruary 14, 2025 | markets.businessinsider.comOutlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate UpdateFebruary 14, 2025 | globenewswire.comOutlook Therapeutics® Participates in Virtual Investor “What This Means” SegmentFebruary 4, 2025 | globenewswire.comOutlook Therapeutics appoints Faisal Sukhtian as chairmanFebruary 3, 2025 | thepharmaletter.comOutlook Therapeutics names new chairman amid product launchJanuary 31, 2025 | msn.comOutlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of DirectorsJanuary 31, 2025 | globenewswire.comOutlook Therapeutics announces presentation of data from NORSE EIGHTJanuary 23, 2025 | markets.businessinsider.comOutlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMDJanuary 23, 2025 | globenewswire.comOutlook Therapeutics, Inc. Announces Presentation by Lawrence A. Kenyon at Webull Corporate Connect Webinar on January 29, 2025January 22, 2025 | quiverquant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOTLK Company DescriptionsOutlook Therapeutics NASDAQ:OTLK$1.40 -0.10 (-6.35%) Closing price 04:00 PM EasternExtended Trading$1.42 +0.02 (+1.07%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Insiders Sell: This Is What It Means for the Market Oklo’s Stock Price Meltdown Is an Opportunity to Buy Top Dividend Stocks With Over 10 Years of Hikes—and Room to Grow Quantum Gamble? Is IonQ's Stock an Opportunity or a Mirage? Will CrowdStrike's FedRAMP Authorization Move CRWD Stock? Top 3 Insider Stock Buys in March—Are They Still Good in April? Taiwan Semiconductor Attracts Big Money on NVIDIA Chip Growth D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
